Modulate Bio develops novel small molecule therapies targeting neurological disorders by leveraging a platform for differentiated GABA A positive allosteric modulators. This approach allows for precise control over receptor subunit activation to maximize efficacy while minimizing off-target side effects. The company is currently advancing candidates for conditions such as Essential Tremor and epilepsy.
Funding
$400K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for neurological disorders like essential tremor, epilepsy, and anxiety often come with significant side effects, such as sedation, limiting their tolerability and effectiveness for many patients. There remains a significant unmet need for therapies that can provide efficacy without these debilitating side effects.
Solution
Modulate Bio is developing a new generation of high-precision neuromedicines based on GABAA positive allosteric modulators to treat neurological disorders, including essential tremor, epilepsy, and anxiety. The company's platform enables the creation of small molecule drugs that selectively modulate GABAA receptor subunits, providing efficacy without the sedative effects associated with traditional treatments like benzodiazepines and neurosteroids. Modulate Bio focuses on validated biological targets, employing translational assays to ensure an efficient route to clinical proof-of-mechanism. The company has established proof of concept in animal models for essential tremor and epilepsy and is close to identifying a development candidate for essential tremor.
Target Audience
The primary target audience includes patients suffering from neurological disorders such as essential tremor, epilepsy, and anxiety, as well as the physicians who treat them.
Features
- Development of novel, differentiated GABAA positive allosteric modulators
- Small molecule drugs designed for controlled oral administration
- Focus on validated biological targets with strong translational assays
- Computational drug discovery platform
- Preclinical proof-of-concept established in animal models of epilepsy and tremors
- Designed to avoid sedative effects associated with current treatments
- Platform applicable to a range of CNS indications beyond essential tremor and epilepsy, including anxiety and depression